



JCO5 RECEIVED 26 MAR 2002 #9

EXPRESS MAIL CERTIFICATE

Date 3/26/02 Label No. EV 039141049 US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D. SAVIS
Name (Print)

D. I. Savis
Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 2292/0H795

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robert Ian LECHLER; Anthony DORLING

Serial No.: 09/674,462

Art Unit: 2645

Confirmation No.: 8594

Filed: October 30, 2000

Examiner:

For: IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2
(B7/CD28 INTERACTION)

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

March 26, 2002


Sir:

In response to the Notification of Missing Requirements, attached please find a copy of the Sequence Listing submitted on March 15, 2002. We are not resending the diskette at this time as it was sent to the United States Patent and

Trademark Office on March 15, 2002.

A copy of the Notification of Missing Requirements is also enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Paul F. Fehner", with a horizontal line drawn underneath it.

Paul F. Fehner, Ph.D.

Reg. No. 35,135

Attorney for Applicants

DARBY & DARBY, P.C.
Post Office Box 5257
New York, N.Y. 10150-5257
Phone (212) 527-7700

PFF



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 101
 United States Patent and Trademark Office
 Washington, D.C. 20503
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 09/674,462	FIRST NAMED APPLICANT Robert Ian Lechler	ATTY DOCKET NO. 2292/011795
DUE: <u>MAY 13, 2002</u> Docketed on <u>3/22</u> by <u>DP</u> for Docketed without file <input type="checkbox"/> Attorney <u>PFF</u>		INTERNATIONAL APPLICATION NO. PCT/GB99/01350 I.A. FILING DATE 04/30/1999 PRIORITY DATE 04/30/1998
Darby & Darby 805 Third Avenue New York, NY 10022-7513		CONFIRMATION NO. 8594 371 FORMALITIES LETTER *OC000000007629707*

Date Mailed: 03/13/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Assignee Statement
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Preliminary Amendments
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN R MCLEAN

Telephone: (703) 308-9117

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO
09/674,462	PCT/GB99/01350	2292/OH795

Return of this card properly stamped, will acknowledge receipt
of:

**Submission of Sequence Listing and Statement
Pursuant to 37 C.F.R. Section 1.821; diskette**

Applicant : Lechler et al
Serial No. : 09/674,462
Filed : October 30, 2000
For : IMMUNOSUPPRESSION BY BLOCKING T
**CELL CO-STIMULATION SIGNAL 2 (B7/CD28
INTERACTION)**

EV03914011418

Attorney : Paul F. Fehlner, Ph.D./sg
File No. : 2292/0H795

Mailed : 3/15/02 Mailer 40